Synapse

← Deepak L. Bhatt

Papers by Deepak L. Bhatt

Page 5 · newest first

  1. Perspectives on Artificial Intelligence in Medical Publishing: A Survey of Medical Journal Editors2025
  2. Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor TherapyArteriosclerosis Thrombosis and Vascular Biology · 2025
  3. Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease.2025
  4. Effects of Eicosapentaenoic Acid vs Eicosapentaenoic/Docosahexaenoic Acids on Cardiovascular MortalityJACC Advances · 2025
  5. Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-ITEuropean Journal of Preventive Cardiology · 2025
  6. Association between lipoprotein(a) and cardiovascular events in patients with peripheral artery disease: the Mass General Brigham Lp(a) registry.2025
  7. Trials on Timing of Cardiovascular Medication AdministrationJACC Advances · 2025
  8. Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT‐MIESC Heart Failure · 2025
  9. Galectin‐3 and kidney function in type 2 diabetes treated with dapagliflozin: Analysis from DECLARE‐TIMI 58ESC Heart Failure · 2025
  10. Representation of Older Adults and Women in Randomized Trials of Noninvasive Imaging for Chest PainCirculation Cardiovascular Imaging · 2025
  11. Transendocardial Injection of Expanded Autologous CD34+ Cells After Myocardial InfarctionJACC Heart Failure · 2025
  12. Cardiovascular-Focused Messaging to Improve Influenza Vaccination RatesNEJM Evidence · 2025
  13. Rapid Titration of Heart Failure Therapies by EtiologyJACC Heart Failure · 2025
  14. In-Hospital Mortality in Hemorrhagic Myocardial InfarctionNEJM Evidence · 2025
  15. Eicosapentaenoic acid (EPA) limits the more rapid oxidation of lipoprotein(a) [Lp(a)] compared with other ApoB particlesCardiovascular Research · 2025
  16. Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES TrialJournal of the American Heart Association · 2025
  17. Effects of purified eicosapentaenoic acid versus mixed eicosapentaenoic/docosahexaenoic acid pharmacotherapies on coronary plaque volume: network meta-analysis of prospective coronary imaging trials.2025
  18. Perspectives on Artificial Intelligence in Medical Publishing: A Survey of Medical Journal EditorsJournal of Cardiovascular Pharmacology · 2025
  19. Fully Automated Diagnosis of Acute Myocardial Infarction Using Electrocardiograms and Multimodal Deep LearningJACC Advances · 2025
  20. First myocardial infarction: risk factors, symptoms, and medical therapyEuropean Heart Journal · 2025
  21. Impact of Sex and Age on Trends of Mortality From Infective Endocarditis in High-Income CountriesJACC Advances · 2025
  22. Burden and severity of respiratory syncytial virus infection in adults with cardiovascular diseases: A systematic literature reviewProgress in Cardiovascular Diseases · 2025
  23. International expert consensus on surgery for type 2 diabetes mellitusBMC Endocrine Disorders · 2025
  24. Secondary analysis of the EMPACT-MI trial reveals cardiovascular–kidney efficacy and safety of empagliflozin after acute myocardial infarctionNature Cardiovascular Research · 2025
  25. P2Y₁₂inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trialsBMJ · 2025
  26. One- versus three-month DAPT after everolimus-eluting stent implantation in diabetic patients at high bleeding risk: results from the XIENCE Short DAPT programmeEuroIntervention · 2025
  27. Icosapent ethyl reduces arterial thrombosis by inhibition of cyclooxygenase-1–induced platelet reactivityScience Translational Medicine · 2025
  28. Differential effect of triglycerides on the prognosis of patients with a first versus recurrent acute coronary syndromeEuropean Journal of Clinical Investigation · 2025
  29. Acute coronary syndromes: mechanisms, challenges, and new opportunitiesEuropean Heart Journal · 2025
  30. Percutaneous Coronary Intervention Outcomes by 5 Major Race and Ethnic SubgroupsJACC Advances · 2025
  31. An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor AgonistsENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2025
  32. Representation of Older Adults and Women in Randomized Trials of Non-Invasive Imaging for Chest Pain2025
  33. Sex Differences in the Association Between Lipoprotein(a) and Cardiovascular Outcomes: The MGB Lp(a) RegistrySHILAP Revista de lepidopterología · 2025
  34. Performance of PREVENT equations for cardiovascular risk prediction in young patients with myocardial infarction: From the MGB YOUNG-MI registryAmerican Journal of Preventive Cardiology · 2025
  35. Outcomes Following Minimally Invasive Surgery for Intracerebral Hemorrhage in the AHA Get With The Guidelines-Stroke RegistryStroke · 2025
  36. Quantifying the Unknowns of Plaque Morphology: The Role of Topological Uncertainty in Coronary Artery DiseaseMayo Clinic Proceedings Digital Health · 2025
  37. Multi-instance learning with attention mechanism for coronary artery stenosis detection on coronary computed tomography angiographyEuropean Heart Journal - Digital Health · 2025
  38. Cardiometabolic risk factors and disease trends for atrial fibrillation in individuals with type 1 diabetes: a nationwide registry studyCardiovascular Diabetology · 2025
  39. Great debate: default duration of dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndrome should be 12 monthsEuropean Heart Journal · 2025
  40. Emerging Pathways of Action of Eicosapentaenoic Acid (EPA)JACC Basic to Translational Science · 2025
  41. Clinical practice patterns among older multimorbid adults presenting with suspected ischemic symptoms: A multi-center surveyAmerican Heart Journal Plus Cardiology Research and Practice · 2025
  42. Long-Term, Patient-Level Analysis of Radiofrequency Renal Denervation in the SYMPLICITY Clinical Trial ProgramJACC Advances · 2025
  43. Variation in Likelihood of Undergoing Percutaneous Coronary Intervention for ST‐Segment–Elevation Myocardial Infarction Among US HospitalsSHILAP Revista de lepidopterología · 2025
  44. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low‐Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE‐IT Randomized TrialJournal of the American Heart Association · 2025
  45. Emerging agents targeting triglyceridesCurrent Opinion in Lipidology · 2025
  46. Patient Enrollment for Cardiovascular Clinical Trials in the United StatesJAMA Cardiology · 2025
  47. Apolipoprotein C3 and risk of cardiovascular events and death in patients on optimized statin treatment after recent acute coronary syndromeEuropean Journal of Preventive Cardiology · 2025
  48. Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized TrialDiabetes Care · 2025
  49. Expanding the triglyceride range in clinical trials: therapeutic opportunitiesEuropean Heart Journal · 2025
  50. Clinical significance of a new diagnosis of atrial fibrillation in patients with vascular diseaseHeart Rhythm · 2025